🧪
hypothesis

eIF2alpha Dephosphorylation Threshold Prevents Pro-Apoptotic ATF4/CHOP Activation

Hypothesis

eIF2alpha Dephosphorylation Threshold Prevents Pro-Apoptotic ATF4/CHOP Activation

Low-dose trazodone reduces phosphorylation of eIF2alpha, shifting translational control away from ATF4-dependent pro-apoptotic gene expression while preserving adaptive stress response genes.
🧬 p-eIF2alpha (Ser51), ATF4, CHOP (DDIT3)🎯 Composite 44%💱 $0.55▲8.6%proposed
neurodegeneration
EvidencePending (0%)📖 0 cit🗣 1 debates 9 support 3 oppose
✓ All Quality Gates Passed
Mechanistic 0.53 (15%) Evidence 0.38 (15%) Novelty 0.00 (12%) Feasibility 0.00 (12%) Impact 0.00 (12%) Druggability 0.00 (10%) Safety 0.00 (8%) Competition 0.00 (6%) Data Avail. 0.00 (5%) Reproducible 0.00 (5%) KG Connect 0.50 (8%) 0.445 composite
☰ Compare⚔️ Duel⚛️ Collide
📄 Export LaTeX
arXiv PreprintNeurIPSNature MethodsPLOS ONE
📖 Export BibTeXinteract with this hypothesis
Composite44%

🧪 Overview

Low-dose trazodone reduces phosphorylation of eIF2alpha, shifting translational control away from ATF4-dependent pro-apoptotic gene expression while preserving adaptive stress response genes. This creates a stress-resilient neuronal phenotype resistant to A-beta-mediated apoptosis. However, human AD brain tissue shows sustained PERK activation that correlates with cognitive decline, and direct PERK inhibitors produced pancreatic toxicity and were abandoned. The mechanistic chain from trazodone to eIF2alpha dephosphorylation via sigma-1 is long and uncertain.

🧬 Mechanism

🧬 Curated Mechanism Pathway

Curated pathway from expert analysis

flowchart TD
    A["Low-Dose Trazodone<br/>Integrated Stress Response"]
    B["p-eIF2alpha Ser51<br/>Phosphorylation Reduced"]
    C["ATF4 Translation<br/>Attenuated"]
    D["CHOP DDIT3 Pro-Apoptotic<br/>Gene Expression Reduced"]
    E["Adaptive Stress Response<br/>Genes Preserved"]
    F["Stress-Resilient Neuronal<br/>Phenotype"]
    G["Resistance to Abeta-Mediated<br/>Apoptosis"]
    A --> B
    B --> C
    C --> D
    D --> F
    B --> E
    E --> F
    F --> G
    style A fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
    style B fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
    style D fill:#b71c1c,stroke:#ef9a9a,color:#ef9a9a
    style G fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7

⚖️ Evidence

⚖️ Evidence Matrix3 supports3 contradicts
Supports
eIF2alpha phosphorylation status determines cell fate under ER stress
PMID:14730311
Supports
Chemical UPR modulation prevents neurodegeneration in prion disease models
PMID:24199970
Supports
Trazodone-derived compound restores proteostasis in neurodegeneration models
PMID:28803823
Contradicts
PERK inhibitor GSK2606414 abandoned due to pancreatic toxicity; human pathway more complex than preclinical indicated
PMID:31539650
Contradicts
AD genetic risk factors (APOE4, TREM2) do not converge on ER stress/UPR pathways as central mediators
PMID:30617331
Contradicts
Mechanistic chain (sigma-1 to eIF2alpha) contains multiple uncertain steps with cumulative probability decline
PMID:31539650
📖 Linked Papers

No linked papers recorded for this hypothesis yet.

🏥 Translation

🧬 3D Protein Structure — P-EIF2ALPHA

No curated PDB or AlphaFold mapping for P-EIF2ALPHA yet. Search RCSB →

🧠 GTEx v10 Brain ExpressionJSON

Median TPM across 13 brain regions for p-eIF2alpha (Ser51), ATF4, CHOP (DDIT3) from GTEx v10.

Cerebellar Hemisphere291 Cerebellum265 Spinal cord cervical c-1257 Frontal Cortex BA9173 Substantia nigra157 Cortex147 Hypothalamus137 Anterior cingulate cortex BA24136 Hippocampus129 Amygdala119 Caudate basal ganglia104 Nucleus accumbens basal ganglia102 Putamen basal ganglia98.4median TPM (GTEx v10)

💉 Clinical Trials

No clinical trials data linked to this hypothesis yet.

No curated ClinVar variants loaded for this hypothesis.

Run scripts/backfill_clinvar_variants.py to fetch P/LP/VUS variants.

🔍 Search ClinVar for p-eIF2alpha (Ser51), ATF4, CHOP (DDIT3) →

No DepMap CRISPR Chronos data found for p-eIF2alpha (Ser51), ATF4, CHOP (DDIT3).

Run python3 scripts/backfill_hypothesis_depmap.py to populate.

🏆 Tournament

🏆 Arenas / Elo

No arena matches recorded yet. Browse Arenas →

📊 Market Indicators

7d Trend
Stable
7d Momentum
▲ 0.0%
Volatility
High
0.1265
Events (7d)
1
Price History
▲8.6%

💾 Resource Usage

No resource usage or linked notebooks recorded for this hypothesis yet.

🔮 Predictions

🔎 Predictions vs Observations2 predictions · 0 with recorded observations
PredictionPredictedObservedStatusConf
IF primary cortical neurons from APP/PS1 mice are treated with trazodone (10 mg/kg i.p., 14 days) while sigma-1 receptor is pharmacologically blocked (BD1063, 5 mg/kg i.p. co-administered), THEN p-eIFSigma-1 antagonism will block trazodone-induced eIF2alpha dephosphorylation (p-eIF2alpha/total eIF2alpha ratio restored to vehicle levels), preventing downstrea— no observation —pending0.65
IF human iPSC-derived cortical neurons (AD genotype, 3突变 carriers) are treated with sub-threshold trazodone (100 nM), threshold trazodone (1 μM), or Aβ42 oligomers (500 nM) for 48 hours, THEN neurons A clear dose-response threshold for trazodone-mediated neuroprotection against Aβ toxicity, with the threshold dose achieving >50% reduction in CHOP (DDIT3) pro— no observation —pending0.58
🔮 Falsifiable Predictions (2)
pendingconf 65%
IF primary cortical neurons from APP/PS1 mice are treated with trazodone (10 mg/kg i.p., 14 days) while sigma-1 receptor is pharmacologically blocked (BD1063, 5 mg/kg i.p. co-administered), THEN p-eIF2alpha levels will remain elevated and cleaved caspase-3 will increase compared to trazodone-only tr
Predicted outcome: Sigma-1 antagonism will block trazodone-induced eIF2alpha dephosphorylation (p-eIF2alpha/total eIF2alpha ratio restored to vehicle levels), preventing
Falsification: Trazodone produces equivalent p-eIF2alpha reduction and neuroprotection regardless of sigma-1 blockade, indicating a sigma-1-independent mechanism for eIF2alpha modulation.
pendingconf 58%
IF human iPSC-derived cortical neurons (AD genotype, 3突变 carriers) are treated with sub-threshold trazodone (100 nM), threshold trazodone (1 μM), or Aβ42 oligomers (500 nM) for 48 hours, THEN neurons receiving 1 μM trazodone + Aβ42 will show ≥50% lower CHOP protein and ≤30% increase in Annexin V+ ce
Predicted outcome: A clear dose-response threshold for trazodone-mediated neuroprotection against Aβ toxicity, with the threshold dose achieving >50% reduction in CHOP (
Falsification: Both sub-threshold and threshold trazodone doses produce equivalent neuroprotection against Aβ, indicating that the protective effect is not dependent on achieving a specific eIF2alpha dephosphorylati
View on SciDEX ↗